Background and purpose: The increased of specific expression of prostate cancer antigen 3 (PCA3)

as one of long non-coding RNA

has been observed in prostate cancer

indicating that PCA3 may contribute to the development of prostate cancer. To further study its roles in prostate cancer

we construct a lentivirus expression vector carrying the whole PCA3. Methods: PCA3 was amplified from prostate cancer cell line LNCaP by reverse transcriptase polymerase chain reaction (RT-PCR). After the sequence was proved to be correct

we recombined the pCDH-CMV-MCS-EF1-copGFP-PCA3. After transformation into E.coli cells

the candidate clones were identified by PCR amplifying

restricting enzyme digestion analysis and DNA sequencing

and the viral titer was determined. Results: Through the Blast analysis software

we compared the results of PCA3 sequence amplified by PCR with GeneBank sequence

finding that the homology is 99.8%. The lentivirus vector was constructed successfully

and the virus in the supernatant reached a titer of 2*108. Conclusion: The successful construction of the lentivirus vector encoding PCA3 not only lays the foundation for the further research into the effect of PCA3 gene on the prostate cancer but also provides a new therapy for advanced prostate cancer.